Paper

Effectiveness of Ginkgo biloba in treating tinnitus: double blind, placebo controlled trial

BMJ 2001; 322 doi: 10.1136/bmj.322.7278.73 (Published 13 January 2001)
Cite this as: BMJ 2001;322:73
  1. Shelley Drew, research associate (s.j.drew{at}bham.ac.uk),
  2. Ewart Davies, senior lecturer
  1. Pharmacology Department, Division of Neuroscience, University of Birmingham, Birmingham B15 2TT
  1. Correspondence to: S Drew

    Abstract

    Objective: To determine whether Ginkgo biloba is effective in treating tinnitus.

    Design: Double blind, placebo controlled trial using postal questionnaires.

    Participants: 1121 healthy people aged between 18 and 70 years with tinnitus that was comparatively stable; 978 participants were matched (489 pairs).

    Intervention: 12 weeks' treatment with either 50 mg Ginkgo biloba extract LI 1370 three times daily or placebo.

    Main outcome measures: Participants' assessment of tinnitus before, during, and after treatment. Questionnaires included items assessing perception of how loud and how troublesome tinnitus was. Changes in loudness were rated on a six point scale. Changes in how troublesome were rated on a five point scale.

    Results: There were no significant differences in primary or secondary outcome measures between the groups. 34 of 360 participants receiving active treatment reported that their tinnitus was less troublesome after 12 weeks of treatment compared with 35 of 360 participants who took placebo.

    Conclusions: 50 mg Ginkgo biloba extract LI 1370 given 3 times daily for 12 weeks is no more effective than placebo in treating tinnitus.

    Footnotes

    • Funding This work was funded by the British Tinnitus Association in conjunction with Lichtwer Pharma UK, manufacturer of the extract used in this study

    • Competing interests The study was financed (two years' salary for SD and running costs) by a contract between the British Tinnitus Association and Lichtwer Pharma GmbH, Berlin, who also supplied the Ginkgo biloba extract and placebo tablets.

      Rapid responses

      THIS WEEK'S POLL

      Read related article

      See previous polls

      BMJ most popular